FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991540282> ?p ?o ?g. }

• W2991540282 endingPage "80" @default.
• W2991540282 startingPage "73" @default.
• W2991540282 abstract "Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and many patients with diabetes have prevalent cardiovascular complications. Recent cardiovascular outcome clinical trials suggest that certain new glucose-lowering drugs are accompanied by additional cardioprotective properties. Indeed, selected glucagon-like peptide-1 receptor agonists have a proved cardiovascular benefit in terms of a reduced incidence of ischaemic events, while sodium/glucose co-transporter-2 inhibitors have also shown significant protection, with a striking effect on heart failure and renal endpoints. These findings have been integrated in recent guidelines which now recommend prescribing (when initial metformin monotherapy fails) a glucagon-like peptide-1 receptor agonist or a sodium/glucose co-transporter-2 inhibitor with clinical trial-confirmed benefit in patients with diabetes and atherosclerotic cardiovascular disease, and a sodium/glucose co-transporter-2 inhibitor in such patients with heart failure or chronic kidney disease at initial stages. Furthermore, the new 2019 European Society of Cardiology guidelines in collaboration with the European Association for the Study of Diabetes recommend a glucagon-like peptide-1 receptor agonist or a sodium/glucose co-transporter-2 inhibitor in treatment-naive patients with type 2 diabetes mellitus with pre-existing cardiovascular disease or at high cardiovascular risk. Future research will disentangle the mechanisms underpinning these beneficial effects and will also establish to what extent these results are generalisable to the whole diabetes population. In the meantime, available evidence should prompt a wide diffusion of these two classes of drugs among patients with diabetes and cardiovascular disease. Here, we briefly summarise recent findings emerging from cardiovascular outcome clinical trials, discuss their impact on treatment algorithms and propose new possible approaches to improve our knowledge further regarding the cardiovascular effect of glucose-lowering medications." @default.
• W2991540282 created "2019-12-05" @default.
• W2991540282 creator A5018275689 @default.
• W2991540282 creator A5019976194 @default.
• W2991540282 creator A5028629999 @default.
• W2991540282 creator A5034052758 @default.
• W2991540282 creator A5041670111 @default.
• W2991540282 creator A5086369928 @default.
• W2991540282 creator A5088452316 @default.
• W2991540282 date "2019-11-26" @default.
• W2991540282 modified "2023-10-18" @default.
• W2991540282 title "Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases" @default.
• W2991540282 cites W1975663485 @default.
• W2991540282 cites W1987941106 @default.
• W2991540282 cites W1996042816 @default.
• W2991540282 cites W2064130493 @default.
• W2991540282 cites W2087528124 @default.
• W2991540282 cites W2135729475 @default.
• W2991540282 cites W2142830692 @default.
• W2991540282 cites W2144325462 @default.
• W2991540282 cites W2146264128 @default.
• W2991540282 cites W2188846692 @default.
• W2991540282 cites W2274836352 @default.
• W2991540282 cites W2282578582 @default.
• W2991540282 cites W2337454357 @default.
• W2991540282 cites W2425644022 @default.
• W2991540282 cites W2519510391 @default.
• W2991540282 cites W2527306919 @default.
• W2991540282 cites W2606281213 @default.
• W2991540282 cites W2608587797 @default.
• W2991540282 cites W2614137535 @default.
• W2991540282 cites W2625031949 @default.
• W2991540282 cites W2626446274 @default.
• W2991540282 cites W2738595939 @default.
• W2991540282 cites W2739090275 @default.
• W2991540282 cites W2746874591 @default.
• W2991540282 cites W2750917994 @default.
• W2991540282 cites W2754041380 @default.
• W2991540282 cites W2755083612 @default.
• W2991540282 cites W2756152366 @default.
• W2991540282 cites W2779223875 @default.
• W2991540282 cites W2795481136 @default.
• W2991540282 cites W2808467887 @default.
• W2991540282 cites W2884466498 @default.
• W2991540282 cites W2885396848 @default.
• W2991540282 cites W2892426086 @default.
• W2991540282 cites W2894746763 @default.
• W2991540282 cites W2894993577 @default.
• W2991540282 cites W2897039855 @default.
• W2991540282 cites W2900413769 @default.
• W2991540282 cites W2917743074 @default.
• W2991540282 cites W2939222610 @default.
• W2991540282 cites W4235845789 @default.
• W2991540282 doi "https://doi.org/10.1177/2047487319880040" @default.
• W2991540282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31766918" @default.
• W2991540282 hasPublicationYear "2019" @default.
• W2991540282 type Work @default.
• W2991540282 sameAs 2991540282 @default.
• W2991540282 citedByCount "50" @default.
• W2991540282 countsByYear W29915402822019 @default.
• W2991540282 countsByYear W29915402822020 @default.
• W2991540282 countsByYear W29915402822021 @default.
• W2991540282 countsByYear W29915402822022 @default.
• W2991540282 countsByYear W29915402822023 @default.
• W2991540282 crossrefType "journal-article" @default.
• W2991540282 hasAuthorship W2991540282A5018275689 @default.
• W2991540282 hasAuthorship W2991540282A5019976194 @default.
• W2991540282 hasAuthorship W2991540282A5028629999 @default.
• W2991540282 hasAuthorship W2991540282A5034052758 @default.
• W2991540282 hasAuthorship W2991540282A5041670111 @default.
• W2991540282 hasAuthorship W2991540282A5086369928 @default.
• W2991540282 hasAuthorship W2991540282A5088452316 @default.
• W2991540282 hasBestOaLocation W29915402821 @default.
• W2991540282 hasConcept C126322002 @default.
• W2991540282 hasConcept C134018914 @default.
• W2991540282 hasConcept C2777180221 @default.
• W2991540282 hasConcept C2778198053 @default.
• W2991540282 hasConcept C2780323712 @default.
• W2991540282 hasConcept C2908647359 @default.
• W2991540282 hasConcept C2910068830 @default.
• W2991540282 hasConcept C535046627 @default.
• W2991540282 hasConcept C555293320 @default.
• W2991540282 hasConcept C71924100 @default.
• W2991540282 hasConcept C98274493 @default.
• W2991540282 hasConcept C99454951 @default.
• W2991540282 hasConceptScore W2991540282C126322002 @default.
• W2991540282 hasConceptScore W2991540282C134018914 @default.
• W2991540282 hasConceptScore W2991540282C2777180221 @default.
• W2991540282 hasConceptScore W2991540282C2778198053 @default.
• W2991540282 hasConceptScore W2991540282C2780323712 @default.
• W2991540282 hasConceptScore W2991540282C2908647359 @default.
• W2991540282 hasConceptScore W2991540282C2910068830 @default.
• W2991540282 hasConceptScore W2991540282C535046627 @default.
• W2991540282 hasConceptScore W2991540282C555293320 @default.
• W2991540282 hasConceptScore W2991540282C71924100 @default.
• W2991540282 hasConceptScore W2991540282C98274493 @default.
• W2991540282 hasConceptScore W2991540282C99454951 @default.
• W2991540282 hasIssue "2_suppl" @default.

• next